The recent ATLANTIC phase II study compared the clinical efficacy of durvalumab as third-line or more for EGFR–/ALK– or EGFR+/ALK+ NSCLC patients according to PD-L1 expression on tumor cells.[33] Patients with EGFR–/ALK– NSCLCs had a higher ORR than those with EGFR+/ALK+ NSCLCs. This evidence concerns the gene ALK and neoplasm.